June 11th 2025

Motive Engineering key account Sensius secures 15 million Euro additional funding

Sensius, a pioneer in precision thermotherapy for oncology and one of Motive Engineering’s key accounts, today announced the successful completion of a €15 million funding round enabled by GrayBella Capital and UCEA Capital Partners, with participation from the EIC Fund and a syndicate of strategic investors. The investment marks a pivotal step forward in Sensius’ mission to transform the treatment of cancer through advanced thermal technologies.

Motive Engineering is Sensius’ partner in creating the treatment simulation and planning software powering this groundbreaking system, designed to precisely control and monitor hyperthermia therapy: a non-invasive treatment that enhances the effectiveness of radiotherapy and chemotherapy.

Our team is working closely with Sensius in developing and ensuring seamless integration of complex components into Sensius’ groundbreaking new system, combining our expertise in medical software development with their innovative approach to patient-centered care.

Motive Engineering CEO Erik Agterhuis: “It’s a continuing privilege to contribute to technology that aims at making cancer treatment more effective for patients worldwide. We congratulate the great team at Sensius with this next milestone in their exciting journey.”

Stay tuned for more updates as this project progresses.